Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Jade Webster, Katie A McNaught, Joanna S Morris
OBJECTIVES: The aim of this study was to determine response rates, median progression-free intervals (PFIs) and median survival times (MSTs) for cats with intermediate-large cell lymphoma treated with a vincristine, cyclophosphamide, mitoxantrone and prednisolone (CMOP) protocol. A secondary objective was to determine the tolerability of mitoxantrone used within this multiagent protocol. METHODS: The medical records of 31 cats treated at a single institution between 2009 and 2022 were reviewed to identify suitable cases...
April 2024: Journal of Feline Medicine and Surgery
#2
JOURNAL ARTICLE
Mamata Ojha, Moumita Banerjee, Madhurima Mandal, Tara Singha, Souvik Ray, Prasanta K Datta, Mahitosh Mandal, Anakuthil Anoop, N D Pradeep Singh
The combined effects of twisted intramolecular charge transfer (TICT) and aggregation-induced emission (AIE) phenomena have demonstrated a significant influence on excited-state chemistry. These combined TICT and AIE features have been extensively utilized to enhance photodynamic and photothermal therapy. Herein, we demonstrated the synergistic capabilities of TICT and AIE phenomena in the design of the photoremovable protecting group (PRPG), namely, NMe2 -Napy-BF2 . This innovative PRPG incorporates TICT and AIE characteristics, resulting in four remarkable properties: (i) red-shifted absorption wavelength, (ii) strong near-infrared (NIR) emission, (iii) viscosity-sensitive emission property, and (iv) accelerated photorelease rate...
April 19, 2024: ACS Applied Materials & Interfaces
#3
Javier Martínez-Caro, Beatriz Agulla, Clàudia Viñeta, Xavier Roura, Montse Mesalles, Josep Pastor
A 10-year-old neutered male Maltese dog was presented for an investigation of lymphocytosis. The dog was up-to-date on vaccinations and deworming. Physical examination did not reveal any significant abnormalities. A complete blood cell count (CBC) showed mild leukocytosis with moderate lymphocytosis, basophilia, and moderate neutropenia, but no significant left shift or toxic change. Serum biochemistry and urinalysis were unremarkable. All performed tests for infectious agents common in this geographical region were negative...
April 15, 2024: Veterinary Clinical Pathology
#4
JOURNAL ARTICLE
Jing Liu, Jie Zhang, Yongteng Zhang, Wei Wei, Meixiao Zhan, Zhiren Zhang, Bing Liu, Xianglong Hu, Weiling He
Chlorambucil (Cbl) is a DNA alkylating drug in the nitrogen mustard family, but the clinical applications of nitrogen mustard antitumor drugs are frequently limited by their poor aqueous solubility, poor cellular uptake, lack of targeting, and severe side effects. Additionally, mitochondria are the energy factories for cells, and tumor cells are more susceptible to mitochondrial dysfunction than some healthy cells, thus making mitochondria an important target for tumor therapy. As a proof-of-concept, direct delivery of Cbl to tumor cells' mitochondria will probably bring about new opportunities for the nitrogen mustard family...
April 9, 2024: Biomaterials Science
#5
JOURNAL ARTICLE
Soumi Kolay, Naveen Kumar, Mohini Guleria, Tapas Das
Chlorambucil is an alkylating drug that finds application towards chemotherapy of different types of cancers. In order to explore the possibility of utilization of this drug as an imaging agent for early diagnosis of solid tumors, attempt was made to synthesize a 99m Tc complex of chlorambucil and evaluate its potential in tumor bearing small animal model. HYNIC-chlorambucil (HYNIC is hydrazine nicotinamide) was synthesized by conjugation of HYNIC with chlorambucil via an ethylenediamine linker. All the intermediates and final product were purified and characterized by standard spectroscopic techniques viz...
April 5, 2024: Bioorganic & Medicinal Chemistry Letters
#6
JOURNAL ARTICLE
Lorris Lecot, Isabelle Desmas-Bazelle, Sarah Benjamin, Pauline De Fornel, Frédérique Ponce, Matthew Kornya, Loïc Desquilbet, Claire Beaudu-Lange, Catherine Ibisch, David Sayag, Ghita Benchekroun, Jérémy Béguin
BACKGROUND: Myeloma-related disorders (MRDs) are rare and poorly documented neoplasms of cats. HYPOTHESIS/OBJECTIVES: To describe clinical, clinicopathologic, and imaging findings, response to treatment, and survival time and to identify factors associated with shorter outcomes in cats with MRD. ANIMALS: Fifty cats with a diagnosis of MRD. METHODS: Cats with paraproteinemia confirmed by serum protein electrophoresis (SPE) and either intramedullary plasmacytosis >10%, marked cytonuclear atypia with intramedullary plasmacytosis that ranged between 5% and 10%, or cytologically or histologically confirmed visceral infiltration were retrospectively included from several veterinary referral centers...
March 22, 2024: Journal of Veterinary Internal Medicine
#7
JOURNAL ARTICLE
Ensieh Poursani, Giuseppe Cirillo, Manuela Curcio, Orazio Vittorio, Michele De Luca, Antonella Leggio, Fiore Pasquale Nicoletta, Francesca Iemma
In this study, we developed self-assembling nanoparticles (LCPs) able to trigger the release of Chlorambucil (Chl) and Doxorubicin (DOX) to MDA-MB-231 cells by exploiting the enzyme and redox signals. The DOX loaded LCPs was prepared by the self-assembly of two chondroitin sulphate (CS) derivatives, obtained by the covalent conjugation of Lipoic Acid (LA) and Chlorambucil (Chl) to the CS backbone. After the physic-chemical characterization of the conjugates by FT-IR, 1 H NMR, and determination of the critical aggregation concentration, spherical nanoparticles with mean hydrodynamic diameter of 45 nm (P...
June 2024: International journal of pharmaceutics: X
#8
REVIEW
Sainath Aher, Jinhua Zhu, Pundlik Bhagat, Laxmikant Borse, Xiuhua Liu
The kinetically inert, six coordinated, octahedral Pt(IV) complexes are termed dual-, triple-, or multi-action prodrugs based on the nature of the axially substituted ligands. These ligands are either inert or biologically active, where the nature of these axial ligands provides additional stability, synergistic biological activity or cell-targeting ability. There are many literature reports from each of these classes, mentioning the varied nature of these axial ligands. The ligands comprise drug molecules such as chlorambucil, doxorubicin, valproic acid, ethacrynic acid, biologically active chalcone, coumarin, combretastatin, non-steroidal anti-inflammatory drugs (NSAIDs) and many more, potentiating the anti-proliferative profile or reducing the side effects associated with cisplatin therapy...
February 24, 2024: Topics in Current Chemistry (Journal)
#9
JOURNAL ARTICLE
Ni-Na Cai, Wan-Yi Liu, Zhi-Qiang Liu, Jia-Hui Gong, Yi-Ling Lin, Ze-Chuan Wang, Yue-Qin Huang, Jian-Xin Guo
OBJECTIVE: To investigate the toxic effect of chlorambucil combined with ibrutinib on mantle cell lymphoma (MCL) cell line Jeko-1 and its related mechanism. METHODS: The MCL cell line Jeko-1 was incubated with different concentrations of chlorambucil or ibrutinib or the combination of the two drugs, respectively. CCK-8 assay was used to detect the proliferation of the cells, and Western blot was used to measure the protein expression levels of BCL-2, caspase-3, PI3K, AKT and P-AKT...
February 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
#10
JOURNAL ARTICLE
Anastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, Pierre Feugier, Monica Tani, Hervé Ghesquières, Gerardo Musuraca, Francesca Gaia Rossi, Francesco Merli, Romain Guièze, Emmanuel Gyan, Guido Gini, Dario Marino, Remy Gressin, Franck Morschhauser, Federica Cavallo, Francesca Palombi, Annarita Conconi, Benoît Tessoulin, Hervé Tilly, Manuela Zanni, Maria Giuseppina Cabras, Enrico Capochiani, Catello Califano, Melania Celli, Alessandro Pulsoni, Francesco Angrilli, Ubaldo Occhini, René-Olivier Casasnovas, Guillaume Cartron, Liliana Devizzi, Corinne Haioun, Anna Marina Liberati, Roch Houot, Michele Merli, Giuseppe Pietrantuono, Francesca Re, Michele Spina, Francesco Landi, Franco Cavalli, Francesco Bertoni, Davide Rossi, Nicoletta Ielmini, Elena Borgo, Stefano Luminari, Emanuele Zucca, Catherine Thieblemont
The IELSG38 trial was conducted to investigate the effects of subcutaneous (SC) rituximab on the complete remission (CR) rate and the benefits of SC maintenance in patients with extranodal marginal zone lymphoma (MZL) who received frontline treatment with chlorambucil plus rituximab. Study treatment comprised an induction phase with chlorambucil 6 mg/m2/day orally on weeks 1-6, 9-10, 13-14, 17-18, and 21-22, and rituximab 375 mg/m2 intravenously on day 1 of weeks 1-4, and 1400 mg SC on weeks 9, 13, 17, and 21...
February 22, 2024: Haematologica
#11
Lijun Yang, Congrou Zhang, Chunhua Ren, Jinjian Liu, Yumin Zhang, Jing Wang, Fan Huang, Lei Zhang, Jianfeng Liu
No abstract text is available yet for this article.
February 15, 2024: ACS Applied Materials & Interfaces
#12
JOURNAL ARTICLE
Phuong-Thao Dang-Luong, Hong-Phuc Nguyen, Loc Le-Tuan, Xuan-Thang Cao, Vy Tran-Anh, Hieu Vu Quang
Theragnostics has become a popular term nowadays, since it enables both diagnosis and therapy at the same time while only using one carrier platform. Therefore, formulating a nanocarrier system that could serve as theragnostic agent by using simple techniques would be an advantage during production. In this project, we aimed to develop a nanocarrier that can be loaded with the chemotherapeutic medication chlorambucil and magnetic resonance imaging agents (e.g., iron oxide nanoparticles and near-infrared fluorophore IR780) for theragnostics...
2024: Beilstein Journal of Nanotechnology
#13
REVIEW
Yanhua Li, Ziqing Gao, Jianhong Zhu, Jianan Su, Pengwei Chen, Jiande Li, Min Feng
PURPOSE: Idiopathic membranous nephropathy (IMN) with moderate risk or above was recommended to receive immunosuppressive therapy. We attempted to evaluate the optimal dose of glucocorticoid when combined with evidence-proven effective immunosuppressants by network meta-analysis. METHODS: A systematic review of the literature was conducted in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov from inception until January 2022. Randomized controlled trials (RCTs) in IMN limited to supportive care, glucocorticoids, cyclophosphamide, chlorambucil, calcineurin inhibitors (CNIs), and rituximab were screened...
January 2024: Curēus
#14
Bruna Voltolin de Sena, Bárbara Correa de Mello, Rodrigo Dos Santos Horta, Mariana de Pádua Costa, Marilia Martins Melo, Reysla Maria da Silveira Mariano, Rodolfo Cordeiro Giunchetti, Antonio Giuliano, Fabiola de Oliveira Paes Leme, Adriano de Paula Sabino, Paulo Ricardo de Oliveira Paes
BACKGROUND: Canine T-zone lymphoma (TZL) is recognized as an indolent CD45-T cell lymphoma, with low aggressiveness and high overall survival. The diagnosis is obtained by histopathology and immunohistochemistry, but also by cytological examination of the lymph node associated with immunophenotyping. Lymphocytosis is commonly identified as around 10,000 cells/µl and may reach 30,760 cells/µl. CASE DESCRIPTION: The present report describes a case of a female Golden Retriever, nine years old, with generalized lymphadenopathy...
December 2023: Open Veterinary Journal
#15
JOURNAL ARTICLE
Dan Zhao, Yixin Zhang, Ziming Yan, Yue Ding, Fengming Liang
Hypoxia in most solid tumors is a major challenge for photodynamic therapy (PDT), and the combination of hypoxia-activated chemotherapy and PDT is a promising approach for enhanced anticancer activity. Herein, we designed hypoxia-responsive polymeric nanoprodrug PNPs to co-deliver photosensitizer 5,10,5,20-tetrakis(4-aminophenyl)-porphine (TAPP) and chlorambucil (CB) to improve the overall therapeutic efficacy. Upon laser irradiation, the central TAPP converted oxygen to produce single oxygen (1 O2 ) for PDT and induced PDT-reduced hypoxia environment, which accelerated the release of activated CB for synergetic cancer cell killing...
January 9, 2024: ACS Omega
#16
JOURNAL ARTICLE
Woojin Lim, Sungji Moon, Na Rae Lee, Ho Gyun Shin, Su-Yeon Yu, Jung Eun Lee, Inah Kim, Kwang-Pil Ko, Sue K Park
We aimed to summarize the cancer risk among patients with indication of group I pharmaceuticals as stated in monographs presented by the International Agency for Research on Cancer working groups. Following the PRISMA guidelines, a comprehensive literature search was conducted using the PubMed database. Pharmaceuticals with few studies on cancer risk were identified in systematic reviews; those with two or more studies were subjected to meta-analysis. For the meta-analysis, a random-effects model was used to calculate the summary relative risks (SRRs) and 95% confidence intervals (95% CIs)...
January 3, 2024: Scientific Reports
#17
JOURNAL ARTICLE
Chiung-Wen Hu, Yuan-Jhe Chang, Wei-Hung Chang, Marcus S Cooke, Yet-Ran Chen, Mu-Rong Chao
Exposure to the physicochemical agents that interact with nucleic acids (NA) may lead to modification of DNA and RNA (i.e., NA modifications), which have been associated with various diseases, including cancer. The emerging field of NA adductomics aims to identify both known and unknown NA modifications, some of which may also be associated with proteins. One of the main challenges for adductomics is the processing of massive and complex data generated by high-resolution tandem mass spectrometry (HR-MS/MS)...
December 28, 2023: Environmental Science & Technology
#18
JOURNAL ARTICLE
Emanuele Cencini, Natale Calomino, Anna Sicuranza, Alessandro Gozzetti, Alberto Fabbri, Monica Bocchia
The management of small lymphocytic lymphoma (SLL) as chronic lymphocytic leukemia (CLL) or an indolent non-Hodgkin lymphoma is highly debated. In this single-center, real-life study, 38 SLL patients managed between 2008 and 2022 were evaluated. Overall, 26/38 cases (68.4%) needed treatment and all but one received CLL concordant therapy, including BR (9/38 cases), fludarabine, cyclophosphamide, rituximab (5/38 cases), rituximab and chlorambucil (4/38 cases), BTK inhibitors (7/38 cases) and steroid (1 case with immune thrombocytopenia)...
December 11, 2023: Journal of Chemotherapy
#19
JOURNAL ARTICLE
Chaitra Ujjani
The treatment landscape of chronic lymphocytic leukemia (CLL) has evolved considerably over the past decade due to the development of effective novel agents with varying mechanisms of action, including Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL2) inhibitors. Extrapolating upon the success of anti-CD20-directed chemoimmunotherapy, a dual-targeted approach has been explored in treatment-naive patients with CLL. Anti-CD20 monoclonal antibody combinations with BTK inhibitors as well as BCL2 inhibitors have demonstrated superiority over traditional cytotoxic chemoimmunotherapy regimens such as fludarabine, cyclophosphamide, and rituximab; bendamustine-rituximab; and obinutuzumab-chlorambucil...
December 8, 2023: Hematology—the Education Program of the American Society of Hematology
#20
JOURNAL ARTICLE
Yixian Fu, Yahui Huang, Chenchen Zhou, Xinge Li, Guoqiang Dong, Min Huang, Jian Ding, Chunquan Sheng
Nicotinamide adenine dinucleotide (NAD) is essentially involved in many biological processes of cancer cells, yet chemical intervention of NAD biosynthesis failed to obtain an optimal therapeutic benefit. We herein developed a new strategy to induce catastrophic NAD depletion by concurrently impairing NAD synthesis and promoting NAD consumption. We designed a series of new compounds that conjugate an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), a rate-limiting enzyme in the NAD salvage pathway, with a DNA-alkylating agent...
December 7, 2023: Journal of Medicinal Chemistry
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
